Kolumne, ORE

Original-Research: Nynomic AG - von NuWays AG Einstufung von NuWays AG zu Nynomic AG Unternehmen: Nynomic AG ISIN: DE000A0MSN11 Anlass der Studie: Update Empfehlung: BUY seit: 18.12.2023 Kursziel: EUR 54 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: Analyst: Christian Sandherr Bolt-on acquisition with high synergy potential; chg.

18.12.2023 - 09:01:42

Original-Research: Nynomic AG (von NuWays AG): BUY


Original-Research: Nynomic AG - von NuWays AG

Einstufung von NuWays AG zu Nynomic AG

Unternehmen: Nynomic AG
ISIN: DE000A0MSN11

Anlass der Studie: Update
Empfehlung: BUY
seit: 18.12.2023
Kursziel: EUR 54
Kursziel auf Sicht von: 12 Monaten
Letzte Ratingänderung: 
Analyst: Christian Sandherr

Bolt-on acquisition with high synergy potential; chg.
 
Topic: Nynomic announced the 100% acquisition of art photonic (13th pillar
of the Nynomic group), which should be highly value accretive during the
coming years thanks to significant synergy potential.
 
In detail, art photonic is a Berlin-based expert in the development and
production of highly specialized fiber optic cables used for optical
measurement technology with a focus on mid-infrared (MIR) wavelength,
making it highly compatible with the the recently acquired NLIR (early
Oct.). Its products enable ultra-fast transmission of light to the
measurement point and back to the sensor to process the received data. Both
acquisitions support Nynomic's strategy to bring MIR in a scalable way into
production processes integrated into stationary machines, production
plants, commercial vehicles and similar, thus expanding Nynomic's future
solution portfolio.
 
In 2023e, art photonics is seen to generate some EUR 4m sales with an EBIT
margin of roughly 10% (eNuW). Thanks to significant cross-selling
opportunities across Nynomic's broad customer base, we expect art
photonic's annual sales growth potential to be at around 20% for the next
three to four years. The resulting positive operating leverage should
quickly enable EBIT margins of >15%, in our
view. While the purchase price was not disclosed, we expect it to be in
line with Nynomic's recent acquisitions, i.e. ~1x EV/sales, or EUR 4m in the
case of art photonics, making it a clearly value accretive deal.
 
Additional acquisitions to follow in H1 2024e. Carried by its inherently
cash flow generating business model, the EUR 18.9m capital increase in May
and in line with its buy and build strategy, Nynomic looks set to acquire
1-2, potentially also larger targets with up to EUR 20m sales during FY
2024e.
 
Further positive newsflow to stem from a strong Q4 and a continued strong
momentum throughout 2024e. Following solid 9M results with EUR 83m sales and
a 10% EBIT margin, Nynomic looks set to report a disproportionally strong
Q4 due to confirmed call-off dates of formerly delayed orders, several new
projects within structurally growing markets. Q4 sales should come in at EUR
37.6m (+14% yoy, eNuW) with an EBIT margin of 19.7% (eNuW). With several
products (e.g. Spectral Engines) beginning to gain traction and
structurally growing demand for existing solutions, organic sales growth
during the next years should exceed 10% (eNuW).
 
BUY with an unchanged EUR 54 PT based on DCF.

Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/28555.pdf
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.

Kontakt für Rückfragen
NuWays AG  - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++

-------------------übermittelt durch die EQS Group AG.-------------------


Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. 
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

@ dpa.de

Weitere Meldungen

Original-Research: ParTec AG (von First Berlin Equity Research GmbH): Buy Original-Research: ParTec AG - from First Berlin Equity Research GmbH 22.11.2024 / 11:20 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 11:21) weiterlesen...

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research... Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 11:06) weiterlesen...

Original-Research: ad pepper media International N.V. (von First Berlin Equit... Original-Research: ad pepper media International N.V. - from First Berlin Equity Research GmbH 22.11.2024 / 10:45 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 10:46) weiterlesen...

Original-Research: NFON AG (von NuWays AG): Buy Original-Research: NFON AG - from NuWays AG 22.11.2024 / 09:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 09:06) weiterlesen...

Original-Research: Nabaltec AG (von NuWays AG): Buy Original-Research: Nabaltec AG - from NuWays AG 22.11.2024 / 09:01 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 09:02) weiterlesen...

Original-Research: mVISE AG (von NuWays AG): Buy Original-Research: mVISE AG - from NuWays AG 22.11.2024 / 09:01 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 09:01) weiterlesen...